CD44 expression is selectively over-expressed in estrogen receptor (ER)- and progesterone receptor (PR)-negative breast tumors, with enrichment detected in basal-like breast cancer (BLBC) [5–7]. This evidence concerns the gene ESR1 and breast cancer.